Update On Phase 3 Librexia ACS Trial

RefinitivLess than 1 min read

Bristol-Myers Squibb Co BMY:

UPDATE ON PHASE 3 LIBREXIA ACS TRIAL
BRISTOL-MYERS SQUIBB CO - LIBREXIA ACS TRIAL DISCONTINUED DUE TO EFFICACY CONCERNS
BRISTOL-MYERS SQUIBB CO - NO NEW SAFETY CONCERNS IDENTIFIED FOR MILVEXIAN
BRISTOL-MYERS SQUIBB CO - LIBREXIA AF AND STROKE STUDIES CONTINUE, DATA EXPECTED 2026

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Login or create a forever free account to read this news